Vol 119, No 1 (Supplement) 2014
Supplement abstract

A new animal model of chemotherapy induced peripheral neurotoxicity: the immune-deficient mouse

Published 2015-03-19


  • Peripheral neurotoxicity,
  • anticancer drugs,
  • animal model

How to Cite

Carozzi, V., Chiorazzi, A., Canta, A., Meregalli, C., Oggioni, N., Avezza, F., Cavaletti, G., & Marmiroli, P. (2015). A new animal model of chemotherapy induced peripheral neurotoxicity: the immune-deficient mouse. Italian Journal of Anatomy and Embryology, 119(1), 37. Retrieved from https://oajournals.fupress.net/index.php/ijae/article/view/2390


Cisplatin, paclitaxel and bortezomib are anticancer drugs widely employed in the treatment of different solid tumours even though peripheral neurotoxicity represents a major limitation in their clinical use. During the last decades many rat and mouse models of chronic chemotherapyinduced peripheral neurotoxicity (CIPN) have been characterized from the clinical, pathological, neurophysiological and behavioural point of view. These models were based on immune-competent animals, however in preclinical oncology immune-deficient mice are mainly used. In this respect, the development of immune-deficient mice models could represent a basis for the concurrent investigation of both anticancer drug efficacy and neurotoxicity in animals implanted with human-derived cancer. Moreover, in the same model, neuroprotective effects and non-interference with anticancer activity could be better studied. In this study we established the feasibility of new immune-deficient murine models of peripheral neurotoxicity induced by three anticancer drugs. Forty-eight athymic nude mice were randomized in 4 groups of 12 animals, three were treated respectively with cisplatin, paclitaxel and bortezomib, and one was left untreated. All animals were followed up for 6 weeks. They were examined at baseline, week 4 and 6 for neurophysiological functions and behavioural tests, whilst morphological and morphometric analysis were performed on dorsal root ganglia (DRG) and peripheral nerves collected after 4 and 6 weeks of treatment. The results of the study demonstrate that athymic nude mice show CIPN features similar to those observed in conventional models even if some differences must be remarked as the prolonged time of treatment required to develop a chronic neuropathy. The characterization of this new mice model of CIPN will allow studies of antineoplastic and neurotoxic effects in the same animal.